Safety monitoring study for Capivasertib in Korea
Part of Cancer, Skin clinical trials.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a patient in South Korea who is eligible for and currently using Capivasertib as approved by local health authorities.
- You must give written permission (informed consent) to take part, or have a legal representative do so.
- You cannot be taking part in any other clinical trial while receiving this drug.
- You must be using Capivasertib only for its approved uses in Korea, not for any other condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
This study follows people in South Korea who have a specific lung cancer genetic change called “exon 14 skipping” and are going to take Tabrecta (capmatinib). It helps collect real-world safety and results for using this medicine under routine care.
This study collects information on how well Imjudo and Imfinzi work in real-world settings for patients who are prescribed these drugs as part of standard care in South Korea. It helps doctors understand how these treatments perform outside of clinical trials.
This study looks at how patients with certain conditions are doing while taking Koselugo (selumetinib) in real life. It's a way to gather information about the treatment's effectiveness and safety outside of a controlled clinical trial.
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.